ESPR Q2 2019 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$519M

Q2 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$982,000

Gross Profit

-$42M-4257.2% margin

Operating Income

-$55M-5631.2% margin

Net Income

-$54M-5521.5% margin

EPS (Diluted)

$-2.01

QoQ Revenue Growth

-99.3%

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$54M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$309M

Total Liabilities

$179M

Stockholders' Equity

$129M

Cash & Equivalents

$274M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$982,000	$0	—
Gross Profit	-$42M	-$40M	-5.8%
Operating Income	-$55M	-$46M	-19.0%
Net Income	-$54M	-$46M	-18.6%

Revenue Segments

Ongoing Regulatory And Development Activities Revenue

$1M100%